The incidence of chronic kidney disease (CKD) is increasing worldwide. Cardiovascular
disease (CVD) is strongly associated with CKD and constitutes one of its major causes of …

There is considerable evidence that the potent vasoconstrictor endothelin‐1 (ET‐1)
contributes to the pathogenesis of a variety of cardiovascular diseases. As such …

Localization of endothelin peptides in human kidney. We investigated the synthesis and
localization of endothelin isoforms in the human kidney using the reverse-transcriptase …

Diabetic kidney disease (DKD) remains the most common cause of chronic kidney disease
and multiple therapeutic agents, primarily targeted at the renin-angiotensin system, have …

Within five years of discovering endothelin (ET-1) in 1988, the first report of an orally
available ET receptor antagonist was published. Within twelve years, bosentan, the first ET …

Due to the potent vasoconstrictor action of endothelin-1 and its synthesis throughout the
vasculature and other tissues, most investigators believe that it is an active participant in the …

Abstract Endothelin-1 (ET-1) is a powerful vasoconstrictor and mitogen that contributes to
blood pressure elevation and related vascular remodeling and target organ damage. ET-1 …

The aim of this study was to define the neurohumoral response associated with the renal
hemodynamic perturbations induced by mental stress acting as an adrenergic stimulus. In 8 …

Previous studies have characterized the endothelin peptides (ET-1, ET-2, ET-3) as strong
vasoconstrictors which are possibly involved in the pathogenesis of cardiovascular disease …

Subsequent to the realization that endothelial cells are important regulators of vascular,
immunological, and probably many other functions, endothelial cell biology has rapidly …